Showing results (191-200 of 201) with videos related to

Sort By:
Pageof 21
NEJM AI|April 9, 2026
Brain Health from Sleep EEG: A Multicohort, Deep Learning Biomarker for Cognition, Disease, and MortalityWolfgang Ganglberger, Haoqi Sun, Niels Turley, et al.
Blood|December 1, 2007
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemiaPhilipp le Coutre, Oliver G Ottmann, Francis Giles, et al.
The New England Journal of Medicine|March 15, 2003
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaStephen G O'Brien, François Guilhot, Richard A Larson, et al.
Translational Psychiatry|October 10, 2018
Elevated expression of a minor isoform of ANK3 is a risk factor for bipolar disorderTimothy Hughes, Ida E Sønderby, Tatiana Polushina, et al.
The Lancet. Oncology|April 17, 2016
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trialJeffrey H Lipton, Charles Chuah, Agnès Guerci-Bresler, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 4, 2025
Assessing the Global Impact of Brain Small Vessel Disease on Cognition: The Multi-Ethnic Study of AtherosclerosisSokratis Charisis, Tanweer Rashid, Christina Dintica, et al.
Cold Spring Harbor Perspectives in Biology|July 19, 2017
Role of the β Common (βc) Family of Cytokines in Health and DiseaseTimothy R Hercus, Winnie L T Kan, Sophie E Broughton, et al.
Blood|August 20, 2010
Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNAHelen E White, Paul Matejtschuk, Peter Rigsby, et al.
Scientific Reports|December 29, 2018
Meta-analysis of Alzheimer's disease on 9,751 samples from Norway and IGAP study identifies four risk lociAree Witoelar, Arvid Rongve, Ina S Almdahl, et al.
The New England Journal of Medicine|December 8, 2006
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemiaBrian J Druker, François Guilhot, Stephen G O'Brien, et al.
Pageof 21